[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rectal-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rectal-tumor":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,77,102,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284",false,"NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.","ALL","18 Years",{"count":20,"type":21},8000,"ESTIMATED","2 Years","OBSERVATIONAL","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","RECRUITING","2026-03-03",{"date":67,"type":68},"2026-03-05","ACTUAL",{"date":70,"type":68},"2019-02-01",{"date":72,"type":21},"2030-08-01",{"name":74,"class":75},"UMC Utrecht","OTHER",18,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100611149","a-comparison-of-endoscopic-synchronous-injection-and-submucosal-dissectionesisd-and-conventional-endoscopic-submucosal-dissectioncesd-for-granular-mixed-nodular-laterally-spreading-tumor-in-the-rectum-lst-g-m-100611149","NCT07236827","A Comparison of Endoscopic Synchronous Injection and Submucosal Dissection(ESISD) and Conventional Endoscopic Submucosal Dissection(CESD) for Granular Mixed Nodular Laterally Spreading Tumor in the Rectum (LST-G-M)","ESISD vs CESD","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Endoscopic diagnosis of a large (≥ 20 mm) granular mixed nodular laterally spreading tumor (LST-G-M) located in the rectum.\n3. Lesion situated 0-15 cm from the anal verge.\n4. Pre-procedure imaging (e.g., EUS) and endoscopic assessment suggest a very low to low risk of lymph node metastasis (i.e., lesions confined to the mucosa or with superficial submucosal invasion \\\u003C 1000 μm).\n5. Deemed suitable for Endoscopic Submucosal Dissection (ESD) based on a comprehensive clinical evaluation by the endoscopist.\n6. Provision of signed and dated informed consent form.\n\nExclusion Criteria:\n\n1. Coagulopathy that cannot be adequately corrected, including an international normalized ratio (INR) \\> 1.5 or a platelet count \\\u003C 50,000\u002FμL.\n2. Evidence of deep submucosal invasion (≥ 1000 μm) or obvious non-lifting sign, suggesting a need for surgical intervention.\n3. Pregnancy or lactation.\n4. Inability to tolerate deep sedation or general anesthesia.\n5. History of colorectal surgery (except for simple appendectomy or polypectomy).\n6. Presence of a synchronous colorectal cancer that requires priority treatment.\n7. Recurrent lesions at the same site.\n8. Any condition that, in the investigator's opinion, could increase the patient's risk or interfere with the study assessments.",{"count":85,"type":21},60,"INTERVENTIONAL",[88],"NA","What is the study about? This study introduces and evaluates a new endoscopic technique called Endoscopic Synchronized Injection and Submucosal Dissection (ESISD). It is designed to remove large, flat precancerous growths in the rectum, known as Granular Mixed Nodular Laterally Spreading Tumors (LST-G-M). We compared this new technique to the standard procedure, Conventional Endoscopic Submucosal Dissection (ESD), to see if it is safer, faster, and more efficient.\n\nWho is this for? This research is intended for patients with large, flat rectal polyps, their families seeking the latest treatment options, and healthcare providers interested in advancements in minimally invasive gastroenterology procedures.",[91,39],"Endoscopic Resection","NOT_YET_RECRUITING","2025-11-14",{"date":95,"type":68},"2025-11-19",{"date":97,"type":21},"2025-12-01",{"date":99,"type":21},"2026-12-31",{"name":101,"class":75},"Taihe Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":86,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":132},"100376703","efficacy-and-safety-of-the-cg-100-intraluminal-bypass-device-100376703","NCT04184973","Efficacy and Safety of the CG-100 Intraluminal Bypass Device","Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial","Inclusion Criteria:\n\n1. The patient is willing to comply with protocol-specified follow-up evaluations\n2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.\n3. Patient is diagnosed with colorectal cancer\n4. Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge\n5. Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation.\n6. Patient is scheduled to undergo mechanical bowel preparation\n7. The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).\n\nExclusion Criteria:\n\n1. Patient has local or systemic infection at the time of intervention (e.g., peritonitis)\n2. Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion).\n3. Patients with ASA classification \\> 3\n4. Albumin \\\u003C 30 g\u002Fliter\n5. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease\n6. Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression\n7. BMI ≥ 40\n8. Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery.\n9. The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor.\n10. Patient has been taking regular systemic\u002F steroid medication in the last 6 months.\n11. Patients is taking antimetabolites or antiplatelet agents.\n12. Patient has preexisting sphincter problems\n13. Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis.\n14. Patients with massive diverticulosis at the sigmoid\u002Fdescending colon (viewed on preoperative CT)\n15. Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data\n16. Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.","22 Years","70 Years",{"count":112,"type":21},250,[88],"A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.",[38,39,116],"Rectal\u002FAnal",[118,119,120,121,122],"anastomosis","leak","mesorectal","ileostomy","colostomy","2025-10-21",{"date":125,"type":68},"2025-10-23",{"date":127,"type":68},"2020-06-23",{"date":99,"type":21},{"name":130,"class":131},"Colospan Ltd.","INDUSTRY",14,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":86,"phases":143,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100510952","study-of-the-prevalence-of-sexual-dysfunction-in-women-after-rectal-cancer-surgery-and-analysis-of-the-impact-of-a-sexologist-intervention-100510952","NCT05933122","Study of the Prevalence of Sexual Dysfunction in Women After Rectal Cancer Surgery and Analysis of the Impact of a Sexologist Intervention","RectSexQol","Inclusion Criteria:\n\n* Women\n* Diagnosis of stage I-III rectal adenocarcinoma or rectosigmoid junction with anastomosis less than 15 cm from the anal margin\n* Surgical management, preceded or not by Radio-chemotherapy, with restoration of continuity\n* Age : over 18\n* Proficiency in French or English\n\nExclusion Criteria:\n\n* Current pregnancy\n* Significant cognitive\u002Fpsychiatric disorders\n* Guardianship","FEMALE",{"count":142,"type":21},144,[88],"RectSexQoL is a study aiming at determining the prevalence of female sexual dysfunction after rectal cancer surgery. It has the goal as well to analyse the impact of an intervention given by a sexologist to such patients.",[39,146,147,148],"Women","Sexuality","Life Quality",[150,151,152,153],"rectal cancer","women","sexuality","quality of life","2024-11-27",{"date":156,"type":68},"2024-12-02",{"date":158,"type":68},"2024-04-03",{"date":160,"type":21},"2027-10",{"name":162,"class":75},"University Hospital, Limoges",6]